Can-Fite Biopharma Ltd Sponsored ADR (Israel)
| AMEX: CANF | Healthcare / Biotechnology / Israel |
| 2.49 | -0.1599 | -6.03% | Vol 4.49K | 1Y Perf -65.58% |
| Oct 2nd, 2023 15:58 DELAYED |
| BID | 2.49 | ASK | 2.51 | ||
| Open | 2.60 | Previous Close | 2.65 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 6.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 161.04 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★+ 49.77 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 12.97 | Earnings Rating | Strong Buy | |
| Market Cap | 10.14M | Earnings Date | 24th Nov 2023 | |
| Alpha | -0.06 | Standard Deviation | 0.20 | |
| Beta | 1.30 |
Today's Price Range 2.492.60 | 52W Range 1.529.00 | 5 Year PE Ratio Range -26.30-12.10 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -3.86% | ||
| 1 Month | -13.24% | ||
| 3 Months | -22.19% | ||
| 6 Months | 13.18% | ||
| 1 Year | -65.58% | ||
| 3 Years | -85.52% | ||
| 5 Years | -98.68% | ||
| 10 Years | -99.74% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -167.47 | |||
ROE last 12 Months | -180.79 | |||
ROA (5Y Avg) | -56.21 | |||
ROA last 12 Months | -110.42 | |||
ROC (5Y Avg) | -174.38 | |||
ROC last 12 Months | -163.68 | |||
Return on invested Capital Q | -28.93 | |||
Return on invested Capital Y | -56.04 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 29.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -10.50 | ||||
| 23.04 | ||||
| 28.97 | ||||
| - | ||||
| -28.10 | ||||
| -0.48 | ||||
| 23.04 | ||||
| 0.27 | ||||
| 5.33M | ||||
| Forward PE | -2.78 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.90 | ||||
| 4.50 | ||||
| 0.00 | ||||
| 0.01 | ||||
| -97.80 | ||||
| Leverage Ratio | 1.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -1 351.40 | ||||
| -1 351.40 | ||||
| -1 115.80 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 613.00K | ||||
| 0.23 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.54 | -0.40 | 25.93 |
| Q01 2023 | - | -0.65 | - |
| Q04 2022 | -0.57 | -1.11 | -94.74 |
| Q03 2022 | -1.00 | -0.90 | 10.00 |
| Q02 2022 | -0.90 | -0.80 | 11.11 |
| Q01 2022 | -1.20 | -0.90 | 25.00 |
| Q04 2021 | -1.80 | -1.90 | -5.56 |
| Q03 2021 | -1.00 | -1.90 | -90.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.53 | 0.00 | - |
| 12/2023 QR | -0.54 | 0.00 | - |
| 12/2023 FY | -2.57 | 0.00 | - |
| 12/2024 FY | -0.95 | 0.00 | - |
| Next Report Date | 24th Nov 2023 |
| Estimated EPS Next Report | -0.53 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 4.49K |
| Shares Outstanding | 4.07K |
| Shares Float | 4.08M |
| Trades Count | 43 |
| Dollar Volume | 11.46K |
| Avg. Volume | 11.48K |
| Avg. Weekly Volume | 14.10K |
| Avg. Monthly Volume | 10.47K |
| Avg. Quarterly Volume | 9.86K |
Can-Fite Biopharma Ltd Sponsored ADR (Israel) (AMEX: CANF) stock closed at 2.49 per share at the end of the most recent trading day (a -6.03% change compared to the prior day closing price) with a volume of 4.49K shares and market capitalization of 10.14M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Can-Fite Biopharma Ltd Sponsored ADR (Israel) CEO is Pnina Fishman.
The one-year performance of Can-Fite Biopharma Ltd Sponsored ADR (Israel) stock is -65.58%, while year-to-date (YTD) performance is -59.38%. CANF stock has a five-year performance of -98.68%. Its 52-week range is between 1.52 and 9, which gives CANF stock a 52-week price range ratio of 12.97%
Can-Fite Biopharma Ltd Sponsored ADR (Israel) currently has a PE ratio of -10.50, a price-to-book (PB) ratio of 23.04, a price-to-sale (PS) ratio of 28.97, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -110.42%, a ROC of -163.68% and a ROE of -180.79%. The company’s profit margin is -%, its EBITDA margin is -1 351.40%, and its revenue ttm is $613.00 Thousand , which makes it $0.23 revenue per share.
Of the last four earnings reports from Can-Fite Biopharma Ltd Sponsored ADR (Israel), there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.53 for the next earnings report. Can-Fite Biopharma Ltd Sponsored ADR (Israel)’s next earnings report date is 24th Nov 2023.
The consensus rating of Wall Street analysts for Can-Fite Biopharma Ltd Sponsored ADR (Israel) is Strong Buy (1), with a target price of $6.5, which is +161.04% compared to the current price. The earnings rating for Can-Fite Biopharma Ltd Sponsored ADR (Israel) stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Can-Fite Biopharma Ltd Sponsored ADR (Israel) has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Can-Fite Biopharma Ltd Sponsored ADR (Israel) has a Sell technical analysis rating based on Technical Indicators (ADX : 30.58, ATR14 : 0.15, CCI20 : -97.43, Chaikin Money Flow : -0.37, MACD : -0.07, Money Flow Index : 52.32, ROC : -13.54, RSI : 41.99, STOCH (14,3) : 22.00, STOCH RSI : 0.35, UO : 38.56, Williams %R : -78.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Can-Fite Biopharma Ltd Sponsored ADR (Israel) in the last 12-months were:
Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
CEO: Pnina Fishman
Telephone: +972 39241114
Address: 10 Bareket Street, Kiryat Matalon, Petah-Tikva 4951778, , IL
Number of employees: 8
